Five patients with a condition known as retinitis pigmentosa will be dealt with at the Manchester Royal Eye Hospital and five at Moorfields Eye Hospital in London one year from now.
They will be given a couple of glasses mounted with a camera that catches light and sends remote signs to an embed in the retina.
Teacher Paulo Stanga, from Manchester Royal Eye Hospital, was included in prior trials utilizing the Argus II Bionic Eye to treat retinitis pigmentosa.
He said: "I'm pleased that our spearheading research has given the proof to bolster NHS England's choice to finance the bionic eye surprisingly for patients.
"It outperformed the greater part of our desires when we understood that one of the retinitis pigmentosa patients in Manchester utilizing the bionic eye could recognize substantial letters without precedent for his grown-up life."
The system will supported by NHS England as a feature of a plan that surveys medicines demonstrating guarantee for what's to come.
Patients will be observed for one year to perceive how the embed enhances their lives.
Keith Hayman, from Lancashire, was one of the first to have the bionic eye embed fitted amid a trial at the Manchester Eye Hospital in 2009.
The 68-year-old, who was determined to have retinitis pigmentosa in his twenties, was compelled to resign as a butcher in 1981 when he got to be distinctly visually impaired.
He said: "Having spent a large portion of my life in haziness, I can now tell when my grandchildren run towards me and make out lights twinkling on Christmas trees.
"When I used to go to the bar, I would converse with a companion, who may have strolled off and I couldn't advise and hushed up about talking.
"This doesn't occur any more since I can tell when they have gone. These seemingly insignificant details have a significant effect to me."
Dr Jonathan Fielden, executive of particular appointing at NHS England said: "This exceptionally creative NHS-supported method demonstrates genuine guarantee and could change lives.
"The NHS has given the world restorative developments extending from advanced waterfall surgery, new immunizations and hip substitutions.
"Presently at the end of the day the NHS is at the cutting edge of bridling momentous science for the advantage patients in this nation."
The Argus II retinal embed, made by Second Sight, has additionally been trialed to treat those torment from age-related macular degeneration - the most widely recognized reason for sight misfortune in the created world with somewhere around 20 and 25 million sufferers around the world.